Posted by Michael Wonder on 14 Jan 2016
FDA issues complete response letter for Kyndrisa for Duchenne muscular dystrophy amenable to exon 51 skipping
14 January 2016 - The FDA has concluded that the standard of substantial evidence of effectiveness has not been met.
For more details, go to: http://investors.bmrn.com/releasedetail.cfm?ReleaseID=950309
